| 1. The role of direct oral anticoagulants in venous thromboembolic disease in gynecologic cancer |
Page:40— |
| 2. The 6th Biennial Meeting of the Asian Society of Gynecologic Oncology, October 10th to 12th, 2019 |
Page:38— |
| 3. The basic principles of oncologic surgery during minimally invasive radical hysterectomy |
Page:33— |
| 4. A significant measure of HPV vaccine effectiveness in a high-risk population in Korea prior to a National Immunization Program |
Page:32— |
| 5. High-risk human papillomavirus testing as a primary screening for cervical cancer: position statement by the Korean Society of Obstetrics and Gynecology and the Korean Society of Gynecologic Oncology |
Page:31— |
| 6. How to predict treatment failure in frail patients with advanced epithelial ovarian cancer: strategies to personalize surgical effort |
Page:26— |
| 7. Japan Society of Gynecologic Oncology 2018 guidelines for treatment of uterine body neoplasms |
Page:18— |
| 8. Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery |
Page:17— |
| 9. Comparison of rivaroxaban and dalteparin for the long-term treatment of venous thromboembolism in patients with gynecologic cancers |
Page:10— |
| 10. An optimized BRCA1/2 next-generation sequencing for different clinical sample types |
Page:9— |
| 11. Surgery of primary sites for stage IVB cervical cancer patients receiving chemoradiotherapy: a population-based study |
Page:8— |
| 12. Selection criteria and colpotomic approach for safe minimally invasive radical hysterectomy in early-stage cervical cancer |
Page:7— |
| 13. ToleRability of BevacizUmab in elderly Ovarian cancer patients (TURBO study): a case-control study of a real-life experience |
Page:6— |
| 14. Maintenance of pegylated liposomal doxorubicin/carboplatin in patients with advanced ovarian cancer: randomized study of an Asian Gynecologic Oncology Group |
Page:5— |
| 15. Status of HPV vaccination among HPV-infected women aged 20–60 years with abnormal cervical cytology in South Korea: a multicenter, retrospective study |
Page:4— |
| 16. Well-trained gynecologic oncologists can perform bowel resection and upper abdominal surgery safely |
Page:3— |
| 17. Clinical response and safety of apatinib monotherapy in recurrent, metastatic cervical cancer after failure of chemotherapy: a retrospective study |
Page:2— |
| 18. The prognostic value of lymph node ratio in stage IIIC cervical cancer patients triaged to primary treatment by radical hysterectomy with systematic pelvic and para-aortic lymphadenectomy |
Page:1— |
| 19. Stage II endometrial cancer requires stratification according to uterine risk factor and sentinel lymph node sampling |
Page:50— |
| 20. In reply: the evaluation of IgG titers' stability from blood samples is necessary |
Page:44— |
| 21. Comments on: a phase 1/2a, dose-escalation, safety and preliminary efficacy study of oral therapeutic vaccine in subjects with cervical intraepithelial neoplasia 3 |
Page:43— |
| 22. Comparison between weekly versus 3-weekly paclitaxel in combination with carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer |
Page:23— |
| 23. Survival and recurrence in stage II endometrial cancers in relation to uterine risk stratification after introduction of lymph node resection and omission of postoperative radiotherapy: a Danish Gynecological Cancer Group Study |
Page:22— |
| 24. Human papillomavirus (HPV) DNA detection in uterine cervix cancer after radiation indicating recurrence: a systematic review and meta-analysis |
Page:20— |
| 25. Significance of PD-L1 expression in carbon-ion radiotherapy for uterine cervical adeno/adenosquamous carcinoma |
Page:19— |
| 26. Completion hysterectomy after chemoradiotherapy for locally advanced adeno-type cervical carcinoma: updated survival outcomes and experience in post radiation surgery |
Page:16— |
| 27. Real world effectiveness and safety of pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer: a Korean multicenter retrospective cohort study |
Page:15— |
| 28. Tozzi classification of diaphragmatic surgery in patients with stage IIIC–IV ovarian cancer based on surgical findings and complexity |
Page:14— |
| 29. Pathologic discrepancies between colposcopy-directed biopsy and loop electrosurgical excision procedure of the uterine cervix in women with cytologic high-grade squamous intraepithelial lesions |
Page:13— |
| 30. Efficacy and safety of neoadjuvant chemotherapy versus primary debulking surgery in patients with ovarian cancer: a meta-analysis |
Page:12— |
| 31. LAMC1 is a prognostic factor and a potential therapeutic target in endometrial cancer |
Page:11— |
| 32. Comparison of rivaroxaban and dalteparin for the long-term treatment of venous thromboembolism in patients with gynecologic cancers |
Page:e10— |
| 33. An optimized BRCA1/2 next-generationsequencing for different clinical sample types |
Page:e9— |
| 34. Surgery of primary sites for stage IVB cervical cancer patients receiving chemoradiotherapy: a population-based study |
Page:e8— |
| 35. Selection criteria and colpotomic approach for safe minimally invasive radical hysterectomy in early-stage cervical cancer |
Page:e7— |
| 36. ToleRability of BevacizUmab in elderly Ovarian cancer patients (TURBO study): a case-control study of a real-life experience |
Page:e6— |
| 37. Maintenance of pegylated liposomal doxorubicin/carboplatin in patients with advanced ovarian cancer: randomized study of an Asian Gynecologic Oncology Group |
Page:e5— |
| 38. Status of HPV vaccination among HPV-infected women aged 20–60 years with abnormal cervical cytology in South Korea: a multicenter, retrospective study |
Page:e4— |
| 39. Well-trained gynecologic oncologists can perform bowel resection and upper abdominal surgery safely |
Page:e3— |
| 40. Clinical response and safety of apatinib monotherapy in recurrent, metastatic cervical cancer after failure of chemotherapy:a retrospective study |
Page:e2— |
| 41. The prognostic value of lymph node ratio in stage IIIC cervical cancer patients triaged to primary treatment by radical hysterectomy with systematic pelvic and para-aortic lymphadenectomy |
Page:e1— |
| 42. The role of direct oral anticoagulants in venous thromboembolic disease in gynecologic cancer |
Page:e40— |
| 43. The 6th Biennial Meeting of the Asian Society of Gynecologic Oncology, October 10th to 12th, 2019 |
Page:e38— |
| 44. The basic principles of oncologic surgery during minimally invasive radical hysterectomy |
Page:e33— |
| 45. A significant measure of HPV vaccine effectiveness in a high-risk population in Korea prior to a National Immunization Program |
Page:e32— |
| 46. High-risk human papillomavirus testing as a primary screening for cervical cancer: position statement by the Korean Society of Obstetrics and Gynecology and the Korean Society of Gynecologic Oncology |
Page:e31— |
| 47. How to predict treatment failure in frail patients with advanced epithelial ovarian cancer: strategies to personalize surgical effort |
Page:e26— |
| 48. Japan Society of Gynecologic Oncology 2018 guidelines for treatment of uterine body neoplasms |
Page:e18— |
| 49. Management of ovarian cancer patients in affected areas during COVID-19 pandemic: Japan and Korea |
Page:e65— |
| 50. A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study |
Page:e61— |
| 51. Robot assisted surgery during the COVID-19 pandemic, especially for gynecological cancer: a statement of the Society of European Robotic Gynaecological Surgery (SERGS) |
Page:e59— |
| 52. National screening programs for cervical cancer in Asian countries |
Page:e55— |
| 53. Management of patients with intermediate-risk early stage cervical cancer |
Page:e54— |
| 54. Nerve-sparing radical hysterectomy in the precision surgery for cervical cancer |
Page:e49— |
| 55. Major clinical research advances in gynecologic cancer in 2019 |
Page:e48— |
| 56. Chemoradiotherapy is not superior to radiotherapy alone after radical surgery for cervical cancer patients with intermediate-risk factor |
Page:e35— |
| 57. Microscopic diseases remain in initial disseminated sites after neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and primary peritoneal cancer |
Page:e34— |
| 58. Risk factors for early death among ovarian cancer patients: a nationwide cohort study |
Page:e30— |
| 59. Sensitizing endometrial cancer to ionizing radiation by multi-tyrosine kinase inhibition |
Page:e29— |
| 60. Quantitative analysis of proteins related to chemoresistance to paclitaxel and carboplatin in human SiHa cervical cancer cells via iTRAQ |
Page:e28— |
| 61. Prognostic significance of lymphovascular space invasion in patients with endometrioid endometrial cancer: a retrospective study from a single center |
Page:e27— |
| 62. Primary sarcoma of the cervix: an analysis of patient and tumor characteristics, treatment patterns, and outcomes |
Page:e25— |
| 63. BRCA1/2 mutation status in patients with metachronous breast and ovarian malignancies: clues towards the implementation of genetic counseling |
Page:e24— |
| 64. Characterizing the efficacy and trends of adjuvant therapy versus observation in women with early stage (uterine confined) leiomyosarcoma: a National Cancer Database study |
Page:e21— |
| 65. Stage II endometrial cancer requires stratification according to uterine risk factor and sentinel lymph node sampling |
Page:e50— |
| 66. In reply: the evaluation of IgG titers' stability from blood samples is necessary |
Page:e44— |
| 67. Comments on: a phase 1/2a, dose-escalation, safety and preliminary efficacy study of oral therapeutic vaccine in subjects with cervical intraepithelial neoplasia 3 |
Page:e43— |
| 68. Comparison between weekly versus 3-weekly paclitaxel in combination with carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer |
Page:e23— |
| 69. Survival and recurrence in stage II endometrial cancers in relation to uterine risk stratification after introduction of lymph node resection and omission of postoperative radiotherapy: a Danish Gynecological Cancer Group Study |
Page:e22— |
| 70. Human papillomavirus (HPV) DNA detection in uterine cervix cancer after radiation indicating recurrence: a systematic review and meta-analysis |
Page:e20— |
| 71. Significance of PD-L1 expression in carbon-ion radiotherapy for uterine cervical adeno/adenosquamous carcinoma |
Page:e19— |
| 72. Completion hysterectomy after chemoradiotherapy for locally advanced adeno-type cervical carcinoma: updated survival outcomes and experience in post radiation surgery |
Page:e16— |
| 73. Real world effectiveness and safety of pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer: a Korean multicenter retrospective cohort study |
Page:e15— |
| 74. Tozzi classification of diaphragmatic surgery in patients with stage IIIC–IV ovarian cancer based on surgical findings and complexity |
Page:e14— |
| 75. Pathologic discrepancies between colposcopy-directed biopsy and loop electrosurgical excision procedure of the uterine cervix in women with cytologic high-grade squamous intraepithelial lesions |
Page:e13— |
| 76. Efficacy and safety of neoadjuvant chemotherapy versus primary debulking surgery in patients with ovarian cancer: a meta-analysis |
Page:e12— |
| 77. LAMC1 is a prognostic factor and a potential therapeutic target in endometrial cancer |
Page:e11— |
| 78. Gynecologic oncology at the time of COVID-19 outbreak |
Page:e72— |
| 79. FIGO staging in ovarian carcinoma and histological subtypes |
Page:e70— |
| 80. Recommendations on management of gynecological malignancies during the COVID-19 pandemic: perspectives from Chinese gynecological oncologists |
Page:e68— |
| 81. Epithelial ovarian cancer: a review of preoperative imaging features indicating suboptimal surgery |
Page:e57— |
| 82. Incidence trends for epithelial peritoneal, ovarian, and fallopian tube cancer during 1999–2016: a retrospective study based on the Korean National Cancer Incidence Database |
Page:e56— |
| 83. Economic burden and treatment patterns of gynecologic cancers in the United States: evidence from the Medical Expenditure Panel Survey 2007–2014 |
Page:e52— |
| 84. Stage III uterine serous carcinoma: modern trends in multimodality treatment |
Page:e53— |
| 85. Comparison of diagnostic accuracy between endometrial curettage and aspiration biopsy in patients treated with progestin for endometrial hyperplasia: a Korean Gynecologic Oncology Group study |
Page:e51— |
| 86. SURF4 maintains stem-like properties via BIRC3 in ovarian cancer cells |
Page:e46— |
| 87. A retrospective study for investigating the relationship between old and new staging systems with prognosis in ovarian cancer using gynecologic cancer registry of Japan Society of Obstetrics and Gynecology (JSOG):disparity between serous carcinoma and clear cell carcinoma |
Page:e45— |
| 88. The impact of systematic retroperitoneal lymphadenectomy on long-term oncologic outcome of women with advanced ovarian clear-cell carcinoma |
Page:e47— |
| 89. The 16-year experience in treating low-risk gestational trophoblastic neoplasia patients with failed primary methotrexate chemotherapy |
Page:e36— |
| 90. Comparing efficacy of high-dose rate brachytherapy versus helical tomotherapy in the treatment of cervical cancer |
Page:e42— |
| 91. Safety evaluation of abdominal trachelectomy in patients with cervical tumors ≥2 cm: a single-institution, retrospective analysis |
Page:e41— |
| 92. Survival benefit of radiation in high-risk, early-stage endometrioid carcinoma |
Page:e39— |
| 93. Feasibility and safety of fertilitysparing surgery in epithelial ovarian cancer with dense adhesion: a longterm result from a single institution |
Page:e85— |
| 94. Comments on: Fertility-sparing treatment for intramucous, moderately differentiated, endometrioid endometrial cancer: a Gynecologic Cancer Inter-Group (GCIG) study |
Page:e96— |
| 95. High mobility group box 3 promotes cervical cancer proliferation by regulating Wnt/β-catenin pathway |
Page:e91— |
| 96. Olaparib and bevacizumab in frontline maintenance of ovarian cancer: an over reliance in unpowered subgroup analysis of the PAOLA-1 trial? |
Page:e95— |
| 97. Impact of COVID-19 in gynecologic oncology: a Nationwide Italian Survey of the SIGO and MITO groups |
Page:e92— |
| 98. The post-progression survival of patients with recurrent or persistent ovarian clear cell carcinoma: results from a randomized phase III study in JGOG3017/GCIG |
Page:e94— |
| 99. Evaluation of the optimal sequence of adjuvant chemotherapy and radiation therapy in the treatment of advanced endometrial cancer |
Page:e90— |
| 100. High expression of maternal embryonic leucine-zipper kinase (MELK) impacts clinical outcomes in patients with ovarian cancer and its inhibition suppresses ovarian cancer cells growth ex vivo |
Page:e93— |
| 101. Reclassification of BRCA1 and BRCA2variants found in ovarian epithelial, fallopian tube, and primary peritoneal cancers |
Page:e83— |
| 102. Management of stage II endometrial cancer and subsequent oncologic outcomes: a National Cancer Database study |
Page:e84— |
| 103. Uterine clear cell carcinoma risk in White versus non-White US subpopulations: does race matter? |
Page:e81— |
| 104. Surviving the COVID-19 pandemic:early response of a gynecologic oncology unit in Singapore |
Page:e77— |
| 105. Kallikrein 5 overexpression is associated with poor prognosis in uterine cervical cancer |
Page:e78— |
| 106. Does adenocarcinoma have a worse prognosis than squamous cell carcinoma in patients with cervical cancer? A real-world study with a propensity score matching analysis |
Page:e80— |
| 107. Surgical or imaging lymph node assessment in locally advanced cervical cancer: a systematic review and meta-analysis |
Page:e79— |
| 108. Pushing the envelope: expanding fertility sparing treatment of endometrial cance |
Page:e82— |
| 109. Fertility-sparing treatment for intramucous, moderately differentiated, endometrioid endometrial cancer: a Gynecologic Cancer Inter-Group (GCIG) study |
Page:e74— |
| 110. Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept |
Page:e86— |
| 111. Erratum: Author Correction.Management of ovarian cancer patients in affected areas during COVID-19 pandemic: Japan and Korea |
Page:e87— |
| 112. Comprehensive pelvic and paraaortic lymphadenectomy in patients with apparently early stage uterine serous carcinoma – an anachronism? |
Page:e76— |
| 113. Potential strategies for prevention of tumor spillage in minimally invasive radical hysterectomy |
Page:e73— |
| 114. Circulating exosomal circFoxp1 confers cisplatin resistance in epithelial ovarian cancer cells |
Page:e75— |
| 115. Vulvar melanoma: an analysis of prognostic factors and treatment patterns |
Page:e66— |
| 116. Feasibility of laparoscopic diaphragmatic peritonectomy during Visceral-Peritoneal Debulking (VPD) in patients with stage IIIC-IV ovarian cancer |
Page:e71— |
| 117. Lymphadenectomy for primary ovarian cancer: a systematic review and meta-analysis |
Page:e67— |
| 118. Should indications for laterally extended endopelvic resection (LEER) exclude patients with sciatica? |
Page:e63— |
| 119. Survival implication of lymphadenectomy in patients surgically treated for apparent early-stage uterine serous carcinoma |
Page:e64— |
| 120. Incidence and clinical course of septic shock in neutropenic patients during chemotherapy for gynecological cancers |
Page:e62— |
| 121. Incidence and predictors of peritoneal metastases of gynecological origin:a population-based study in the Netherlands |
Page:e58— |
| 122. Age-specific predictors of cervical dysplasia recurrence after primary conization: analysis of 3,212 women |
Page:e60— |
| 123. Gynecologic oncology at the time of COVID-19 outbreak |
Page:e72— |
| 124. FIGO staging in ovarian carcinoma and histological subtypes |
Page:e70— |
| 125. Recommendations on management of gynecological malignancies during the COVID-19 pandemic: perspectives from Chinese gynecological oncologists |
Page:e68— |
| 126. Epithelial ovarian cancer: a review of preoperative imaging features indicating suboptimal surgery |
Page:e57— |
| 127. Incidence trends for epithelial peritoneal, ovarian, and fallopian tube cancer during 1999–2016: a retrospective study based on the Korean National Cancer Incidence Database |
Page:e56— |
| 128. Economic burden and treatment patterns of gynecologic cancers in the United States: evidence from the Medical Expenditure Panel Survey 2007–2014 |
Page:e52— |
| 129. Stage III uterine serous carcinoma: modern trends in multimodality treatment |
Page:e53— |
| 130. Comparison of diagnostic accuracy between endometrial curettage and aspiration biopsy in patients treated with progestin for endometrial hyperplasia: a Korean Gynecologic Oncology Group study |
Page:e51— |
| 131. SURF4 maintains stem-like properties via BIRC3 in ovarian cancer cells |
Page:e46— |
| 132. A retrospective study for investigating the relationship between old and new staging systems with prognosis in ovarian cancer using gynecologic cancer registry of Japan Society of Obstetrics and Gynecology (JSOG):disparity between serous carcinoma and clear cell carcinoma |
Page:e45— |
| 133. The impact of systematic retroperitoneal lymphadenectomy on long-term oncologic outcome of women with advanced ovarian clear-cell carcinoma |
Page:e47— |
| 134. The 16-year experience in treating low-risk gestational trophoblastic neoplasia patients with failed primary methotrexate chemotherapy |
Page:e36— |
| 135. Comparing efficacy of high-dose rate brachytherapy versus helical tomotherapy in the treatment of cervical cancer |
Page:e42— |
| 136. Safety evaluation of abdominal trachelectomy in patients with cervical tumors ≥2 cm: a single-institution, retrospective analysis |
Page:e41— |
| 137. Survival benefit of radiation in high-risk, early-stage endometrioid carcinoma |
Page:e39— |
| 138. Feasibility and safety of fertilitysparing surgery in epithelial ovarian cancer with dense adhesion: a longterm result from a single institution |
Page:e85— |
| 139. Comments on: Fertility-sparing treatment for intramucous, moderately differentiated, endometrioid endometrial cancer: a Gynecologic Cancer Inter-Group (GCIG) study |
Page:e96— |
| 140. High mobility group box 3 promotes cervical cancer proliferation by regulating Wnt/β-catenin pathway |
Page:e91— |
| 141. Olaparib and bevacizumab in frontline maintenance of ovarian cancer: an over reliance in unpowered subgroup analysis of the PAOLA-1 trial? |
Page:e95— |
| 142. Impact of COVID-19 in gynecologic oncology: a Nationwide Italian Survey of the SIGO and MITO groups |
Page:e92— |
| 143. The post-progression survival of patients with recurrent or persistent ovarian clear cell carcinoma: results from a randomized phase III study in JGOG3017/GCIG |
Page:e94— |
| 144. Evaluation of the optimal sequence of adjuvant chemotherapy and radiation therapy in the treatment of advanced endometrial cancer |
Page:e90— |
| 145. High expression of maternal embryonic leucine-zipper kinase (MELK) impacts clinical outcomes in patients with ovarian cancer and its inhibition suppresses ovarian cancer cells growth ex vivo |
Page:e93— |
| 146. Reclassification of BRCA1 and BRCA2variants found in ovarian epithelial, fallopian tube, and primary peritoneal cancers |
Page:e83— |
| 147. Management of stage II endometrial cancer and subsequent oncologic outcomes: a National Cancer Database study |
Page:e84— |
| 148. Uterine clear cell carcinoma risk in White versus non-White US subpopulations: does race matter? |
Page:e81— |
| 149. Surviving the COVID-19 pandemic:early response of a gynecologic oncology unit in Singapore |
Page:e77— |
| 150. Kallikrein 5 overexpression is associated with poor prognosis in uterine cervical cancer |
Page:e78— |
| 151. Does adenocarcinoma have a worse prognosis than squamous cell carcinoma in patients with cervical cancer? A real-world study with a propensity score matching analysis |
Page:e80— |
| 152. Surgical or imaging lymph node assessment in locally advanced cervical cancer: a systematic review and meta-analysis |
Page:e79— |
| 153. Pushing the envelope: expanding fertility sparing treatment of endometrial cance |
Page:e82— |
| 154. Fertility-sparing treatment for intramucous, moderately differentiated, endometrioid endometrial cancer: a Gynecologic Cancer Inter-Group (GCIG) study |
Page:e74— |
| 155. Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept |
Page:e86— |
| 156. Erratum: Author Correction.Management of ovarian cancer patients in affected areas during COVID-19 pandemic: Japan and Korea |
Page:e87— |
| 157. Comprehensive pelvic and paraaortic lymphadenectomy in patients with apparently early stage uterine serous carcinoma – an anachronism? |
Page:e76— |
| 158. Potential strategies for prevention of tumor spillage in minimally invasive radical hysterectomy |
Page:e73— |
| 159. Circulating exosomal circFoxp1 confers cisplatin resistance in epithelial ovarian cancer cells |
Page:e75— |
| 160. Vulvar melanoma: an analysis of prognostic factors and treatment patterns |
Page:e66— |
| 161. Feasibility of laparoscopic diaphragmatic peritonectomy during Visceral-Peritoneal Debulking (VPD) in patients with stage IIIC-IV ovarian cancer |
Page:e71— |
| 162. Lymphadenectomy for primary ovarian cancer: a systematic review and meta-analysis |
Page:e67— |
| 163. Should indications for laterally extended endopelvic resection (LEER) exclude patients with sciatica? |
Page:e63— |
| 164. Survival implication of lymphadenectomy in patients surgically treated for apparent early-stage uterine serous carcinoma |
Page:e64— |
| 165. Incidence and clinical course of septic shock in neutropenic patients during chemotherapy for gynecological cancers |
Page:e62— |
| 166. Incidence and predictors of peritoneal metastases of gynecological origin:a population-based study in the Netherlands |
Page:e58— |
| 167. Age-specific predictors of cervical dysplasia recurrence after primary conization: analysis of 3,212 women |
Page:e60— |
